Guggenheim raised the firm’s price target on Cidara Therapeutics (CDTX) to $35 from $33 and keeps a Buy rating on the shares after speaking to management following the company’s Q1 earnings release. The firm remains “bullish” on CD388’s “multi-billion dollar blockbuster opportunity” and views the recent stock decline due to HHS appointments as “completely unfounded given both CDTX’s unique antiviral approach to flu disease prevention and review by CDER,” says the analyst, who “strongly” encourages investors to build a position as anticipation and interest builds ahead of the late June NAVIGATE readout.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CDTX:
- Promising Outlook for Cidara Therapeutics: Buy Rating Affirmed Amid Upcoming R&D Insights and Strategic FDA Engagement
- Cidara Therapeutics price target raised to $47 from $46 at Citizens JMP
- Cidara Therapeutics Reports Q1 2025 Financial Results
- Cidara Therapeutics reports Q1 EPS ($1.66) vs. ($2.28) last year
- Cidara Therapeutics files $500M mixed securities shelf
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue